K 312

Drug Profile

K 312

Alternative Names: K-312

Latest Information Update: 13 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kowa Pharmaceutical
  • Class Antihyperlipidaemics; Small molecules
  • Mechanism of Action Cholesterol ester transfer protein inhibitors; PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dyslipidaemias; Hyperlipidaemia

Most Recent Events

  • 01 Apr 2015 Kowa Pharmaceuticals completes a phase I trial in Dyslipidaemia in USA (NCT02676830)
  • 22 Dec 2014 Phase-I development is ongoing in USA
  • 01 Dec 2013 Kowa completes a phase I trial in Dyslipidaemias (in volunteers) in USA (NCT01952548)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top